Form EFFECT Nasus Pharma Ltd
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 11, 2026 4:15 P.M. |
| Form: | F-3 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
- SEALSQ’s CEO, Carlos Moreira Joins the Board of Trustees of the World Law Foundation and Proposes Creation of a Global AI Chapter
- Wealthbox Brings Advisor CRM Data to "Claude for Financial Advisors"
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
